AEON Clarifies ABP-450 Biosimilar Development Plan

September 30, 2026 — 08:30 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Wednesday, AEON Biopharma (AEON) said FDA feedback from a Type 2b meeting provided clarity on the development pathway for ABP-450 as a biosimilar to BOTOX.

ABP-450 is a botulinum toxin being developed for therapeutic indications. AEON plans to submit an IND for a comparative pharmacodynamic study using Compound Muscle Action Potential (CMAP) measurements in the fourth quarter of 2026.

The FDA indicated that previously completed comparative studies of ABP-450 versus BOTOX could be submitted as supportive evidence, subject to scientific bridging.

AEON does not plan to initiate a standalone comparative efficacy study at this time and will evaluate its analytical, pharmacodynamic and comparative human evidence to determine whether additional clinical studies are needed.

AEON shares closed on Tuesday at $0.25, down 0.99%. In the Premarket trading, shares are up 3.42% at $0.27.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

AEON Clarifies ABP-450 Biosimilar Development Plan

Tags

Latest Articles